VLS-01-203 BU
Phase 2Small molecule
VLS-01-203 BU is one of 30 small molecule programs targeting Treatment Resistant Depression. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Treatment Resistant Depression
#DrugCompanyPhaseTrials
1Ketalar
AAultman Health Foundation
Approved
Spravato
WWim Janssens
Approved
Risperdal
WWim Janssens
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Bayer Aspirin
BayerApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Abilify
OtsukaApproved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Mirapex
Boehringer IngelheimApproved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VLS-01-203 BU. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- Aatai Therapeutics, Inc.